{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:08Z","timestamp":1772166548609,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU20-09-00066"],"award-info":[{"award-number":["NU20-09-00066"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["320360"],"award-info":[{"award-number":["320360"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["Cooperatio (HEAS)"],"award-info":[{"award-number":["Cooperatio (HEAS)"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Knowledge of co-occurring mental disorders (termed \u2018dual diagnosis\u2019) among patients receiving opioid agonist treatment (OAT) is scarce. This study aimed (1) to estimate the prevalence and structure of dual diagnoses in two national cohorts of OAT patients and (2) to compare mental disorders between OAT patients and the general populations stratified on sex and standardized by age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A registry-linkage study of OAT patients from Czechia (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20094,280) and Norway (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200911,389) during 2010\u20132019 was conducted. Data on mental disorders (F00-F99; ICD-10) recorded in nationwide health registers were linked to the individuals registered in OAT. Dual diagnoses were defined as any mental disorder excluding substance use disorders (SUDs, F10-F19; ICD-10). Sex-specific age-standardized morbidity ratios (SMR) were calculated for 2019 to compare OAT patients and the general populations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of dual diagnosis was 57.3% for Czechia and 78.3% for Norway. In Czechia, anxiety (31.1%) and personality disorders (25.7%) were the most prevalent, whereas anxiety (33.8%) and depression (20.8%) were the most prevalent in Norway. Large country-specific variations were observed, e.g., in ADHD (0.5% in Czechia, 15.8% in Norway), implying differences in screening and diagnostic practices. The SMR estimates for any mental disorders were 3.1 (females) and 5.1 (males) in Czechia and 5.6 (females) and 8.2 (males) in Norway. OAT females had a significantly higher prevalence of co-occurring mental disorders, whereas SMRs were higher in OAT males. In addition to opioid use disorder (OUD), other substance use disorders (SUDs) were frequently recorded in both countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results indicate an excess of mental health problems in OAT patients compared to the general population of the same sex and age in both countries, requiring appropriate clinical attention. Country-specific differences may stem from variations in diagnostics and care, reporting to registers, OAT provision, or substance use patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-024-00467-5","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:12:58Z","timestamp":1715645578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-7449","authenticated-orcid":false,"given":"Gabriela","family":"Rolov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Gabrhel\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Mrav\u010d\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingvild","family":"Odsbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"467_CR1","doi-asserted-by":"crossref","unstructured":"Santo T, Campbell G, Gisev N, Martino-Burke D, Wilson J, Colledge-Frisby S et al. Prevalence of mental disorders among people with opioid use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. 2022;238.","DOI":"10.1016\/j.drugalcdep.2022.109551"},{"key":"467_CR2","doi-asserted-by":"crossref","unstructured":"Rogers AH, Zvolensky MJ, Ditre JW, Buckner JD, Asmundson GJG. Association of opioid misuse with anxiety and depression: a systematic review of the literature. Clin Psychol Rev. 2021;84.","DOI":"10.1016\/j.cpr.2021.101978"},{"key":"467_CR3","unstructured":"Babor T, Campbell R, Room R, Saunders J, editors. Lexicon of alcohol and drug terms. 2nd ed. World Health Organization; 1994."},{"issue":"1","key":"467_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12954-020-00396-x","volume":"17","author":"KA Morin","year":"2020","unstructured":"Morin KA, Eibl JK, Gauthier G, Rush B, Mushquash C, Lightfoot NE, et al. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data. Harm Reduct J. 2020;17(1):51.","journal-title":"Harm Reduct J"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.drugalcdep.2014.12.025","volume":"148","author":"KM Bogdanowicz","year":"2015","unstructured":"Bogdanowicz KM, Stewart R, Broadbent M, Hatch SL, Hotopf M, Strang J, et al. Double trouble: Psychiatric comorbidity and opioid addiction\u2014all-cause and cause-specific mortality. Drug Alcohol Depend. 2015;148:85\u201392.","journal-title":"Drug Alcohol Depend"},{"key":"467_CR6","doi-asserted-by":"crossref","unstructured":"Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ et al. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021;228.","DOI":"10.1016\/j.drugalcdep.2021.108996"},{"issue":"4","key":"467_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","volume":"28","author":"L Amato","year":"2005","unstructured":"Amato L, Davoli M, A.Perucci C, Ferri M, Faggiano F, Mattick P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321\u20139.","journal-title":"J Subst Abuse Treat"},{"key":"467_CR8","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Db Syst Rev. 2009;3.","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"467_CR9","doi-asserted-by":"crossref","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Db Syst Rev 2016(5).","DOI":"10.1002\/14651858.CD011117.pub2"},{"issue":"3","key":"467_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/00952990.2021.1887202","volume":"47","author":"E Moazen-Zadeh","year":"2021","unstructured":"Moazen-Zadeh E, Ziafat K, Yazdani K, Kamel MM, Wong JSH, Modabbernia A, et al. Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials. Am J Drug Alcohol Abus. 2021;47(3):280\u2013304.","journal-title":"Am J Drug Alcohol Abus"},{"issue":"10208","key":"467_CR11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: Harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379.","journal-title":"Lancet"},{"issue":"1","key":"467_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/add.15594","volume":"117","author":"Y-I Hser","year":"2022","unstructured":"Hser Y-I, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, et al. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022;117(1):151\u201361.","journal-title":"Addiction"},{"key":"467_CR13","doi-asserted-by":"crossref","unstructured":"Aas CF, Vold JH, Gjestad R, Skurtveit S, Lim AG, Gjerde KV et al. Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway. Subst Abuse Treat Prev Policy. 2021;16(1).","DOI":"10.1186\/s13011-021-00354-1"},{"key":"467_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.psychres.2016.06.024","volume":"243","author":"C Roncero","year":"2016","unstructured":"Roncero C, Barral C, Rodr\u00edguez-Cintas L, P\u00e9rez-Pazos J, Martinez-Luna N, Casas M, et al. Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: the PROTEUS study. Psychiatry Res. 2016;243:174\u201381.","journal-title":"Psychiatry Res"},{"issue":"6","key":"467_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.addbeh.2009.01.002","volume":"34","author":"CE Grella","year":"2009","unstructured":"Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6):498\u2013504.","journal-title":"Addict Behav"},{"issue":"3","key":"467_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.addbeh.2013.11.022","volume":"39","author":"EM Goldner","year":"2014","unstructured":"Goldner EM, Lusted A, Roerecke M, Rehm J, Fischer B. Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav. 2014;39(3):520\u201331.","journal-title":"Addict Behav"},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.drugalcdep.2018.12.030","volume":"197","author":"CM Jones","year":"2019","unstructured":"Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78\u201382.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"467_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drugalcdep.2012.06.020","volume":"127","author":"JD Savant","year":"2013","unstructured":"Savant JD, Barry DT, Cutter CJ, Joy MT, Dinh A, Schottenfeld RS, et al. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine\/naloxone treatment. Drug Alcohol Depend. 2013;127(1):243\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"467_CR19","unstructured":"Torrens M, Mestre-Pint\u00f3 J-I, Domingo-Salvany A. Comorbidity of substance use and mental disorders in Europe. 2015."},{"issue":"2","key":"467_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/00952990.2013.842241","volume":"40","author":"ML Griffin","year":"2014","unstructured":"Griffin ML, Dodd DR, Potter JS, Rice LS, Dickinson W, Sparenborg S, et al. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder. Am J Drug Alcohol Abus. 2014;40(2):157\u201362.","journal-title":"Am J Drug Alcohol Abus"},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addbeh.2015.05.001","volume":"48","author":"J Burdzovic Andreas","year":"2015","unstructured":"Burdzovic Andreas J, Lauritzen G, Nordfj\u00e6rn T. Co-occurrence between mental distress and poly-drug use: a ten year prospective study of patients from substance abuse treatment. Addict Behav. 2015;48:71\u20138.","journal-title":"Addict Behav"},{"issue":"4","key":"467_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1600-0447.2008.01244.x","volume":"118","author":"PA Ringen","year":"2008","unstructured":"Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Vaskinn A, et al. The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatrica Scandinavica. 2008;118(4):297\u2013304.","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"10","key":"467_CR23","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1001\/archgenpsychiatry.2011.113","volume":"68","author":"M Nordentoft","year":"2011","unstructured":"Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011;68(10):1058\u201364.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"467_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/08897070802218661","volume":"29","author":"JH Khalsa","year":"2008","unstructured":"Khalsa JH, Treisman G, McCance-Katz E, Tedaldi E. Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse. Substance Abuse. 2008;29(3):5\u201316.","journal-title":"Substance Abuse"},{"issue":"3","key":"467_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11414-010-9227-6","volume":"38","author":"BM Booth","year":"2011","unstructured":"Booth BM, Walton MA, Barry KL, Cunningham RM, Chermack ST, Blow FC. Substance use, depression, and mental health functioning in patients seeking acute medical care in an inner-city ED. J Behav Health Serv Res. 2011;38(3):358\u201372.","journal-title":"J Behav Health Serv Res"},{"key":"467_CR26","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs: Comorbidity of substance use and mental health disorders in Europe. 2016."},{"issue":"1","key":"467_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2478\/nsad-2014-0002","volume":"31","author":"D Morisano","year":"2014","unstructured":"Morisano D, Babor TF, Robaina KA. Co-occurrence of substance use disorders with other psychiatric disorders: implications for treatment services. Nord Stud Alcohol Dr. 2014;31(1):5\u201325.","journal-title":"Nord Stud Alcohol Dr"},{"issue":"1","key":"467_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/08897077.2014.960551","volume":"36","author":"G Carr\u00e0","year":"2015","unstructured":"Carr\u00e0 G, Bartoli F, Brambilla G, Crocamo C, Clerici M. Comorbid addiction and major mental illness in Europe: a narrative review. Substance Abuse. 2015;36(1):75\u201381.","journal-title":"Substance Abuse"},{"key":"467_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jsat.2015.09.006","volume":"61","author":"MA Priester","year":"2016","unstructured":"Priester MA, Browne T, Iachini A, Clone S, DeHart D, Seay KD. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review. J Subst Abuse Treat. 2016;61:47\u201359.","journal-title":"J Subst Abuse Treat"},{"key":"467_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpsychores.2022.111137","volume":"165","author":"S Skarstein","year":"2023","unstructured":"Skarstein S, Lien L, Abebe DS. The burden of somatic diseases among people with alcohol- and drug use disorders are influenced by mental illness and low socioeconomic status. A registry-based cohort study in Norway. J Psychosom Res. 2023;165:111\u201337.","journal-title":"J Psychosom Res"},{"key":"467_CR31","unstructured":"Castelpietra G, Knudsen AKS, Agardh EE, Armocida B, Beghi M, Iburg KM, et al. The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990\u20132019: findings from the global burden of Disease Study 2019. Volume 16. The Lancet Regional Health - Europe; 2022."},{"issue":"3","key":"467_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.21101\/cejph.a4474","volume":"24","author":"R Gabrhel\u00edk","year":"2016","unstructured":"Gabrhel\u00edk R, Nechansk\u00e1 B, Mrav\u010d\u00edk V, Skurtveit S, Lund OI, Handal M. A unique opportunity to study short- and long-term consequences in children prenatally exposed to illicit drugs and opioid maintenance treatment using Czech and Scandinavian registers. Cent Eur J Publ Heal. 2016;24(3):248\u201351.","journal-title":"Cent Eur J Publ Heal"},{"key":"467_CR33","doi-asserted-by":"crossref","unstructured":"Gabrhelik R, Handal M, Mravcik V, Nechanska B, Tjagvad C, Thylstrup B et al. Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study. Bmj Open. 2021;11(5).","DOI":"10.1136\/bmjopen-2020-047028"},{"key":"467_CR34","volume-title":"Gender differences in physical morbidity in opioid agonist treatment patients: Population-based cohort studies from the Czech Republic and Norway","author":"G Rolov\u00e1","year":"2023","unstructured":"Rolov\u00e1 G, Eide D, Gabrhel\u00edk R, Odsbu I, Clausen T, Skurtveit S. Gender differences in physical morbidity in opioid agonist treatment patients: Population-based cohort studies from the Czech Republic and Norway. Volume 18. Prevention, and Policy: Substance Abuse Treatment; 2023."},{"issue":"4","key":"467_CR35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000530822","volume":"29","author":"D Eide","year":"2023","unstructured":"Eide D, Skurtveit S, Clausen T, Hesse M, Mrav\u010d\u00edk V, Nechansk\u00e1 B, et al. Cause-specific mortality among patients in treatment for opioid use disorder in multiple settings: a prospective comparative cohort study. Eur Addict Res. 2023;29(4):272\u201384.","journal-title":"Eur Addict Res"},{"key":"467_CR36","unstructured":"Mrav\u010d\u00edk V. Dotazn\u00edkov\u00e1 studie L\u00e9ka\u0159i \u010cR 2020 se zam\u011b\u0159en\u00edm na problematiku z\u00e1vislost\u00ed. 2021."},{"issue":"1","key":"467_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1403494819859737","volume":"48","author":"IJ Bakken","year":"2020","unstructured":"Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The Norwegian patient Registry and the Norwegian Registry for Primary Health Care: Research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49\u201355.","journal-title":"Scand J Public Health"},{"issue":"2","key":"467_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1742-7843.2009.00494.x","volume":"106","author":"K Furu","year":"2010","unstructured":"Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, S\u00f8rensen HT. The nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86\u201394.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"467_CR39","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.04.019","volume":"24","author":"P Sedova","year":"2015","unstructured":"Sedova P, Brown RD, Zvolsky M, Kadlecova P, Bryndziar T, Volny O, et al. Validation of stroke diagnosis in the National Registry of hospitalized patients in the Czech Republic. J Stroke Cerebrovasc Dis. 2015;24(9):2032\u20138.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"2","key":"467_CR40","first-page":"129","volume":"18","author":"K Furu","year":"2008","unstructured":"Furu K. Establishment of the nationwide Norwegian prescription database (NorPD) \u2013 new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi. 2008;18(2):129\u201336.","journal-title":"Norsk Epidemiologi"},{"key":"467_CR41","unstructured":"Waal H, Bussesund K, Clausen T, Lillevold PH, Skeie I, Statusrapport. 2017. LAR 20 \u00e5r. Status, vurderinger og perspektiver.; 2018."},{"issue":"1","key":"467_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12888-021-03489-4","volume":"21","author":"K Leung","year":"2021","unstructured":"Leung K, Xu E, Rosic T, Worster A, Thabane L, Samaan Z. Sensitivity and specificity of self-reported psychiatric diagnoses amongst patients treated for opioid use disorder. BMC Psychiatry. 2021;21(1):520.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"467_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1192\/bji.2023.25","volume":"20","author":"SK Reitan","year":"2023","unstructured":"Reitan SK, Lien L. Mental health services in Norway, 2023. BJPsych Int. 2023;20(4):95\u20139.","journal-title":"BJPsych Int"},{"issue":"4","key":"467_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/08039488.2022.2105946","volume":"77","author":"L Hellstr\u00f6m","year":"2023","unstructured":"Hellstr\u00f6m L, Gren Voldby K, Eplov LF. Stigma towards people with mental illness in the nordic countries \u2013 A scoping review. Nord J Psychiatry. 2023;77(4):319\u201328.","journal-title":"Nord J Psychiatry"},{"issue":"8","key":"467_CR45","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2215-0366(17)30135-9","volume":"4","author":"P Winkler","year":"2017","unstructured":"Winkler P, Krupchanka D, Roberts T, Kondratova L, Mach\u016f V, H\u00f6schl C, et al. A blind spot on the global mental health map: a scoping review of 25 years\u2019 development of mental health care for people with severe mental illnesses in central and eastern Europe. Lancet Psychiatry. 2017;4(8):634\u201342.","journal-title":"Lancet Psychiatry"},{"key":"467_CR46","doi-asserted-by":"crossref","unstructured":"Evans Lacko S, Form\u00e1nek T, Mlad\u00e1 K, Winkler P. Development of public stigma toward people with mental health problems in Czechia 2013\u20132019. Eur Psychiatry. 2021;64(1).","DOI":"10.1192\/j.eurpsy.2021.2226"},{"key":"467_CR47","unstructured":"Broul\u00edkov\u00e1 HM, Dlouh\u00fd M, Winkler P. Ekonomick\u00e9 hodnocen\u00ed ve zdravotnictv\u00ed: Zam\u011b\u0159eno na du\u0161evn\u00ed zdrav\u00ed. 2020."},{"issue":"3","key":"467_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000520185","volume":"28","author":"F Chalabianloo","year":"2021","unstructured":"Chalabianloo F, Ohldieck C, Haaland \u00d8A, Fadnes LT, Johansson KA. Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence. Eur Addict Res. 2021;28(3):199\u2013209.","journal-title":"Eur Addict Res"},{"key":"467_CR49","doi-asserted-by":"crossref","unstructured":"Mrav\u010d\u00edk V, Jan\u00edkov\u00e1 B, Drbohlavov\u00e1 B, Popov P, Pirona A. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic. Harm Reduct J. 2018;15(1).","DOI":"10.1186\/s12954-018-0268-0"},{"issue":"2","key":"467_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000508571","volume":"27","author":"M Miovsk\u00fd","year":"2021","unstructured":"Miovsk\u00fd M, Lukavsk\u00e1 K, Rub\u00e1\u0161ov\u00e1 E, \u0160\u0165astn\u00e1 L, \u0160efr\u00e1nek M, Gabrhel\u00edk R. Attention deficit hyperactivity disorder among clients diagnosed with a substance use disorder in the therapeutic communities: prevalence and psychiatric comorbidity. Eur Addict Res. 2021;27(2):87\u201396.","journal-title":"Eur Addict Res"},{"issue":"6","key":"467_CR51","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000484240","volume":"23","author":"K Fiksdal Abel","year":"2018","unstructured":"Fiksdal Abel K, Ravndal E, Clausen T, Bramness J\u00f8rgen G. Attention deficit hyperactivity disorder symptoms are common in patients in opioid maintenance treatment. Eur Addict Res. 2018;23(6):298\u2013305.","journal-title":"Eur Addict Res"},{"issue":"1","key":"467_CR52","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s12888-023-04980-w","volume":"23","author":"JH Vold","year":"2023","unstructured":"Vold JH, Halm\u00f8y A, Chalabianloo F, Pierron MC, L\u00f8berg E-M, Johansson KA, et al. Attention-deficit\/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study. BMC Psychiatry. 2023;23(1):479.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"467_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000321259","volume":"17","author":"PJ Carpentier","year":"2010","unstructured":"Carpentier PJ, van Gogh MT, Knapen LJM, Buitelaar JK, De Jong CAJ. Influence of attention deficit hyperactivity disorder and conduct disorder on opioid dependence severity and psychiatric comorbidity in chronic methadone-maintained patients. Eur Addict Res. 2010;17(1):10\u201320.","journal-title":"Eur Addict Res"},{"issue":"Suppl 5","key":"467_CR54","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1177\/1087054711435360","volume":"16","author":"P Asherson","year":"2012","unstructured":"Asherson P, Akehurst R, Kooij JJS, Huss M, Beusterien K, Sasan\u00e9 R, et al. Under diagnosis of adult ADHD: Cultural influences and societal burden. J Atten Disord. 2012;16(Suppl 5):S20\u201338.","journal-title":"J Atten Disord"},{"key":"467_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.mhp.2018.10.003","volume":"12","author":"P K\u00f6ck","year":"2018","unstructured":"K\u00f6ck P, Walter M. Personality disorder and substance use disorder \u2013 an update. Mental Health Prev. 2018;12:82\u20139.","journal-title":"Mental Health Prev"},{"issue":"2","key":"467_CR56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1037\/a0018095","volume":"117","author":"B Bandelow","year":"2010","unstructured":"Bandelow B, Schmahl C, Falkai P, Wedekind D. Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev. 2010;117(2):623\u201336.","journal-title":"Psychol Rev"},{"issue":"6","key":"467_CR57","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/hup.2497","volume":"30","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Wedekind D. Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. Hum Psychopharmacology: Clin Experimental. 2015;30(6):393\u2013415.","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"key":"467_CR58","doi-asserted-by":"crossref","unstructured":"Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. The Cocaine Crisis, 1987; Boston, MA: Springer US.","DOI":"10.1007\/978-1-4613-1837-8_7"},{"issue":"6","key":"467_CR59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1192\/bjp.177.6.486","volume":"177","author":"M Piccinelli","year":"2000","unstructured":"Piccinelli M, Wilkinson G. Gender differences in depression: critical review. Br J Psychiatry. 2000;177(6):486\u201392.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"467_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00737-004-0047-7","volume":"7","author":"M Klose","year":"2004","unstructured":"Klose M, Jacobi F. Can gender differences in the prevalence of mental disorders be explained by sociodemographic factors? Archives Women\u2019s Mental Health. 2004;7(2):133\u201348.","journal-title":"Archives Women\u2019s Mental Health"},{"issue":"7","key":"467_CR61","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/archgenpsychiatry.2009.36","volume":"66","author":"S Seedat","year":"2009","unstructured":"Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, et al. Cross-national associations between gender and mental disorders in the World Health Organization world mental health surveys. Arch Gen Psychiatry. 2009;66(7):785\u201395.","journal-title":"Arch Gen Psychiatry"},{"key":"467_CR62","doi-asserted-by":"crossref","unstructured":"Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. 2017;143:783\u2013822.","DOI":"10.1037\/bul0000102"},{"key":"467_CR63","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cpr.2017.10.012","volume":"66","author":"RK McHugh","year":"2018","unstructured":"McHugh RK, Votaw VR, Sugarman DE, Greenfield SF. Sex and gender differences in substance use disorders. Clin Psychol Rev. 2018;66:12\u201323.","journal-title":"Clin Psychol Rev"},{"issue":"7","key":"467_CR64","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1176\/ps.2009.60.7.880","volume":"60","author":"SF Greenfield","year":"2009","unstructured":"Greenfield SF, Grella CE. Alcohol & drug abuse: what is women-focused treatment for substance use disorders? Psychiat Serv. 2009;60(7):880\u20132.","journal-title":"Psychiat Serv"},{"key":"467_CR65","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Women and drugs: Health and social responses. 2022."},{"key":"467_CR66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jsat.2016.12.013","volume":"75","author":"ADO Verissimo","year":"2017","unstructured":"Verissimo ADO, Grella CE. Influence of gender and race\/ethnicity on perceived barriers to help-seeking for alcohol or drug problems. J Subst Abuse Treat. 2017;75:54\u201361.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"467_CR67","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/17523281.2011.533452","volume":"4","author":"I Sch\u00e4fer","year":"2011","unstructured":"Sch\u00e4fer I, Fischer M, Reimer J, Karow A, Haasen C. Significance of psychiatric comorbidity for the outcome of maintenance treatment \u2013 a review of the literature. Mental Health Subst Use. 2011;4(1):62\u201371.","journal-title":"Mental Health Subst Use"},{"key":"467_CR68","doi-asserted-by":"crossref","unstructured":"Friesen EL, Kurdyak P. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder. Drug Alcohol Depend. 2020;216.","DOI":"10.1016\/j.drugalcdep.2020.108244"},{"key":"467_CR69","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357.","DOI":"10.1136\/bmj.j1550"},{"issue":"1","key":"467_CR70","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/15504263.2018.1518553","volume":"15","author":"V Karapareddy","year":"2019","unstructured":"Karapareddy V. A review of integrated care for concurrent disorders: cost effectiveness and clinical outcomes. J Dual Diagnosis. 2019;15(1):56\u201366.","journal-title":"J Dual Diagnosis"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00467-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00467-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00467-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:21:17Z","timestamp":1715646077000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00467-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00467-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.31219\/osf.io\/szh96","asserted-by":"object"}]},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approvals from the ethics committees in Czechia (no. 36\/19GrantAZVVES20201.LFUK) and Norway (no. 2019\/656\/REC South-East C) have been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Roman Gabrhel\u00edk is the shareholder of Adiquit Ltd., which is currently developing apps for addiction recovery. Nevertheless, no funding was related to this study, and the activities had no role in the study design or the data collection, analysis, interpretation of the data, writing the manuscript, or deciding to submit the paper for publication. The remaining authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}